Back in June, Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), Qlt Inc. and the latter’s subsidiary, Isotope Acquisition Corp., entered into an Agreement......
(read more)September 14 - Hedge Funds, News - Comments
Markets opened higher on Wednesday as investors await the announcement regarding interest rate hike from the Federal Reserve today. Analysts think that......
(read more)June 15 - Market Movers, News - Comments
U.S. stocks look set to end today’s trading session in green territory, having gone through a strong selloff last week. Among them there are several......
(read more)December 21 - Market Movers, News - Comments
Although the market has regained most of the losses from the opening hour, there are some stocks that have remained deep in red. Valeant Pharmaceuticals......
(read more)November 10 - Earnings Report, Market Movers, News, Tech - Comments
Alex Denner is still bullish on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) and has further increased his stake in the company. As reported in a recent......
(read more)September 30 - Hedge Funds, News - Comments
According to a recent 13G form filed with the Securities and Exchange Commission, Kevin Kotler‘s Broadfin Capital has initiated a stake in ContraFect......
(read more)June 22 - Hedge Funds, News - Comments
To say Kevin Kotler’s Broadfin Capital had exceptional Q1 returns from its 11 long positions in companies valued at $1 billion or more would be a gross......
(read more)April 16 - Hedge Funds, News - Comments
At Insider Monkey, we track over 700 of the top hedge funds in the world, following and reporting on their latest moves disclosed through filings with......
(read more)April 2 - Hedge Funds, News - Comments
Kevin Kotler‘s New York-based fund Broadfin Capital has boosted its position in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR). In a new filing with......
(read more)November 7 - Hedge Funds, News - Comments
Steve Cohen’s Point72 Asset Management disclosed today a huge increase in its stake in Lumber Liquidators Holdings Inc (NYSE:LL). The funds affiliated......
(read more)October 16 - Hedge Funds, News - Comments
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) continues to feel hedge funds’ bullishness. Not only did Steve Cohen’s Point72 Asset Management disclose......
(read more)October 15 - Hedge Funds, News - Comments
Life science is turning out to be an industry sector that most hedgies are convinced will outperform in the near future. In the last few days we have......
(read more)October 15 - Hedge Funds, News - Comments
Scopia Capital Management has disclosed in a recent regulatory filing with the Security and Exchange Commission that it has acquired 4.2 million shares......
(read more)August 12 - Hedge Funds, News - Comments
Over the past couple of days, the healthcare sector has witnessed plenty of insider activity, which should not be overlooked. In this article, I will......
(read more)May 8 - Insider Trading - Comments
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), a developer and marketer of RNA-based novel drugs to treat a variety of diseases, has been one of the best......
(read more)September 20 - News - Comments
Big Pharma gets plenty of hype. But is Little Pharma where investors can make the biggest gains? The answer to that question is a resounding “yes......
(read more)September 17 - News - Comments
Should Pacira Pharmaceuticals Inc (NASDAQ:PCRX) investors track the following data? To the average investor, there are many methods market participants......
(read more)September 17 - News - Comments
Biotechnology stocks often trade with excessive valuations, until one day, large losses occur. The best way to protect yourself is to be logical when......
(read more)September 16 - News - Comments
Just after the successful acquisition of Onyx Pharmaceuticals and positive results on AMG-145, a cholesterol-lowering experimental drug, Amgen, Inc......
(read more)September 11 - News - Comments
Make that four collaborations between Biogen Idec Inc. (NASDAQ:BIIB) and ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) in the last two years. The pair announced......
(read more)September 10 - News - Comments
Is Impax Laboratories Inc (NASDAQ:IPXL) a good investment? At the moment, there are tons of indicators shareholders can use to analyze publicly traded......
(read more)September 3 - News - Comments
Santarus, Inc. (NASDAQ:SNTS) has risen over 300% in the past year partly based on sales optimism for ulcerative colitis drug Uceris, which launched in......
(read more)August 28 - News - Comments
To the average investor, there are dozens of gauges market participants can use to watch publicly traded companies. Some of the most under-the-radar are......
(read more)August 26 - News - Comments
The Motley Fool’s readers have spoken, and I have heeded their cries. After months of pointing out CEO gaffes and faux pas, I’ve decided......
(read more)August 7 - News - Comments
As human beings it can sometimes be difficult for us to see the good in a bad situation. In the biotech sector, where developing a drug can cost hundreds......
(read more)August 7 - News - Comments
In America, 33.5% of adults over the age of 20 have high LDL (“bad”) cholesterol levels, according to the CDC. Even though the American Heart Association......
(read more)August 7 - News - Comments
Both ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) and Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) have a single drug in the market that help heart patients......
(read more)August 5 - News - Comments
There are few times when your doctor or physician will utter the phrase, “I don’t know” to a patient, but when you’re dealing......
(read more)August 5 - News - Comments
The US pharmaceutical industry has been revolutionized by the emerging biotech companies which have discovered new ways to cure even the rarest of diseases......
(read more)August 1 - News - Comments
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I’d be unable to keep up on......
(read more)August 1 - News - Comments
Biotech companies sometimes get lucky, launching a drug into a new indication where there’s no competition, but more often than not the biotech......
(read more)June 27 - News - Comments
There are investment opportunities in every sector, but biotechs launching new drugs offer a unique investment opportunity to take advantage of hyper-......
(read more)June 27 - News - Comments
Is Pacira Pharmaceuticals Inc (NASDAQ:PCRX) a superb investment right now? Hedge funds are in an optimistic mood. The number of long hedge fund positions......
(read more)June 12 - News - Comments
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the......
(read more)June 10 - News - Comments
Within the next few days, stocks for two orphan drugmakers could either soar or sink. Both Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) and Raptor Pharmaceutical......
(read more)April 24 - News - Comments
Roche Holding Ltd. (ADR) (PINK:RHHBY) and ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced Monday a new partnership for developing treatments for Huntington......
(read more)April 8 - News - Comments
An interesting method of assessing the direction a stock can take is by monitoring insider purchases. This is because company insiders hold information......
(read more)March 28 - Insider Trading - Comments
With no PDUFA decisions on the plate this week, we’ll instead turn our attention to two important FDA panel meetings and two earnings reports that......
(read more)March 4 - News - Comments
Orphan drugs — medications meant for small patient populations with rare, dangerous diseases — can be a rewarding business for biotech firms......
(read more)February 22 - News - Comments
